IART - Integra LifeSciences Holdings Corp Stock Price, Fair Value and News

24.91USD-0.17 (-0.68%)Market Closed

Market Summary

USD24.91-0.17

Market Closed

-0.68%

IART Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

IART Stock Price

View Fullscreen

IART RSI Chart

IART Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

48.79

Price/Sales (Trailing)

1.28

EV/EBITDA

19.62

Price/Free Cashflow

32.22

IART Price/Sales (Trailing)

IART Profitability

EBT Margin

3.01%

Return on Equity

2.52%

Return on Assets

0.99%

Free Cashflow Yield

3.1%

IART Fundamentals

IART Revenue

Revenue (TTM)

1.5B

Rev. Growth (Yr)

-3.14%

Rev. Growth (Qtr)

-7.09%

IART Earnings

Earnings (TTM)

40.2M

Earnings Growth (Yr)

-113.54%

Earnings Growth (Qtr)

-116.54%

Breaking Down IART Revenue

Last 7 days

-14.7%

Last 30 days

-27.7%

Last 90 days

-40.3%

Trailing 12 Months

-50.2%

How does IART drawdown profile look like?

IART Financial Health

Current Ratio

4.68

Debt/Equity

0.36

Debt/Cashflow

0.23

IART Investor Care

Buy Backs (1Y)

3.79%

Diluted EPS (TTM)

0.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.5B	0	0	0
2023	1.6B	1.5B	1.5B	1.5B
2022	1.6B	1.6B	1.6B	1.6B
2021	1.4B	1.5B	1.5B	1.5B
2020	1.5B	1.4B	1.4B	1.4B
2019	1.5B	1.5B	1.5B	1.5B
2018	1.3B	1.4B	1.5B	1.5B
2017	1.0B	1.0B	1.1B	1.2B
2016	917.0M	953.6M	977.6M	992.1M
2015	816.2M	831.8M	860.6M	882.7M
2014	822.6M	814.1M	798.4M	796.7M
2013	831.3M	826.7M	829.9M	836.2M
2012	795.2M	812.1M	820.0M	830.9M
2011	740.4M	755.1M	770.7M	780.1M
2010	694.2M	707.1M	721.5M	732.1M
2009	0	663.9M	673.2M	682.5M
2008	0	0	0	654.6M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Integra LifeSciences Holdings Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 12, 2024	schwartz eric	sold (taxes)	-51,595	35.88	-1,438	evp, chief legal officer & sec
Mar 12, 2024	davis robert t. jr.	sold (taxes)	-72,621	35.88	-2,024	evp & president, tt
Mar 12, 2024	mcbreen michael j.	sold (taxes)	-72,190	35.88	-2,012	evp & president, css
Mar 12, 2024	mosebrook jeffrey	sold (taxes)	-12,450	35.88	-347	svp, fin & princ acct officer
Mar 11, 2024	schwartz eric	acquired	-	-	16,028	evp, chief legal officer & sec
Mar 11, 2024	de witte jan	sold (taxes)	-7,425	36.22	-205	president & ceo
Mar 11, 2024	veillon-berteloot chantal	acquired	-	-	11,758	evp & chro
Mar 11, 2024	davis robert t. jr.	sold (taxes)	-87,290	36.22	-2,410	evp & president, tt
Mar 11, 2024	davis robert t. jr.	acquired	-	-	20,283	evp & president, tt
Mar 11, 2024	mcbreen michael j.	sold (taxes)	-142,055	36.22	-3,922	evp & president, css

Which funds bought or sold IART recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	Inspire Investing, LLC	added	14.84	-25,065	359,569	0.04%
May 07, 2024	SEI INVESTMENTS CO	unchanged	-	3,449	237,260	-%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	191	791,653	1,368,300	-%
May 07, 2024	PANAGORA ASSET MANAGEMENT INC	added	8.1	-30,318	222,272	-%
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-10.69	-1,029,000	2,741,000	-%
May 07, 2024	Swiss National Bank	reduced	-9.21	-1,641,080	4,647,280	-%
May 07, 2024	Mitsubishi UFJ Asset Management (UK) Ltd.	unchanged	-	-25,000	106,000	0.05%
May 07, 2024	Illinois Municipal Retirement Fund	unchanged	-	-118,000	519,000	0.01%
May 07, 2024	Headlands Technologies LLC	added	54.32	34,445	168,884	0.04%
May 07, 2024	ASSETMARK, INC	unchanged	-	-5,589	24,461	-%

Are Funds Buying or Selling IART?

Are funds buying IART calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IART

No. of Funds

Unveiling Integra LifeSciences Holdings Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	champlain investment partners, llc	3.12%	2,435,957	SC 13G/A
Feb 13, 2024	vanguard group inc	8.97%	7,012,793	SC 13G/A
Feb 09, 2024	wellington management group llp	4.28%	3,349,368	SC 13G/A
Feb 09, 2024	morgan stanley	5.9%	4,634,346	SC 13G/A
Feb 09, 2024	capital research global investors	5.5%	4,297,326	SC 13G
Jan 25, 2024	blackrock inc.	8.5%	6,641,845	SC 13G/A
Feb 14, 2023	tru st partnership, l.p.	10.20%	8,515,930	SC 13G/A
Feb 13, 2023	champlain investment partners, llc	6.30%	5,259,524	SC 13G/A
Feb 09, 2023	morgan stanley	6.8%	5,681,483	SC 13G/A
Feb 09, 2023	vanguard group inc	8.56%	7,147,759	SC 13G/A

Recent SEC filings of Integra LifeSciences Holdings Corp

View All Filings

Date Filed	Form Type	Document
May 06, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
Apr 04, 2024	ARS	ARS
Apr 04, 2024	DEF 14A	DEF 14A
Mar 25, 2024	PRE 14A	PRE 14A
Mar 13, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading

Peers (Alternatives to Integra LifeSciences Holdings Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.6B	40.3B	-5.05%	-4.82%	32.45	4.53	-2.84%	-3.08%
BDX	67.4B	19.7B	-3.45%	-6.52%	50.6	3.42	4.82%	-17.56%
ALGN	20.6B	3.9B	-14.54%	-9.65%	44.54	5.26	5.72%	46.72%
BAX	18.2B	14.9B	-15.38%	-17.01%	6.88	1.22	2.98%	207.68%
MID-CAP
ATR	10.0B	3.5B	7.32%	25.05%	31.94	2.82	6.16%	35.06%
HSIC	9.3B	12.5B	0.39%	-2.78%	24.01	0.75	-0.61%	-18.83%
BIO	7.6B	2.6B	-17.82%	-26.90%	-23.72	2.94	-6.25%	-68.62%
XRAY	5.8B	3.9B	-13.74%	-32.04%	-61.76	1.47	0.23%	91.03%
AXNX	3.4B	387.1M	-0.59%	20.47%	-215.56	8.87	30.82%	65.57%
PDCO	2.3B	6.6B	-1.26%	-0.69%	11.98	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.92%	-14.34%	-1.85	0.4	7.94%	-1661.78%
ANIK	422.2M	169.3M	11.74%	12.93%	-5.49	2.49	7.49%	-244.90%
ANGO	235.9M	324.0M	-10.59%	-34.33%	-1.23	0.73	-3.19%	-337.41%
APYX	46.8M	52.3M	-10.27%	-60.90%	-2.5	0.89	17.61%	19.28%
AEMD	3.3M	3.7M	-25.00%	250.00%	-0.27	0.87	5.77%	8.23%

Integra LifeSciences Holdings Corp News

Latest updates

Integra LifeSciences Holdings Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-7.1%	369	397	382	381	381	398	385	398	377	406	387	390	360	389	370	259	354	395	379	384	360
Costs and Expenses	1.1%	365	361	356	369	344	330	320	338	330	347	330	338	329	336	313	245	327	359	400	338	327
S&GA Expenses	1.6%	166	163	162	165	167	152	144	161	160	162	156	163	157	162	150	116	166	174	173	165	175
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.00	21.00	-	19.00	18.00	18.00
EBITDA Margin	-12.9%	0.14*	0.16*	0.18*	0.21*	0.24*	0.24*	0.23*	0.23*	0.22*	0.25*	0.24*	0.25*	-	-	-	-	-	-	-	-	-
Interest Expenses	-0.9%	14.00	14.00	13.00	12.00	12.00	13.00	13.00	12.00	12.00	12.00	12.00	13.00	13.00	17.00	21.00	16.00	18.00	13.00	14.00	13.00	13.00
Income Taxes	-121.6%	-1.95	9.00	-0.89	-0.36	6.00	11.00	9.00	7.00	6.00	6.00	8.00	10.00	22.00	-53.83	9.00	2.00	2.00	11.00	0.00	7.00	-7.93
Earnings Before Taxes	-118.1%	-5.23	29.00	19.00	4.00	30.00	64.00	59.00	52.00	39.00	52.00	51.00	45.00	67.00	39.00	42.00	2.00	11.00	26.00	-27.51	36.00	25.00
EBT Margin	-42.7%	0.03*	0.05*	0.08*	0.10*	0.13*	0.14*	0.13*	0.12*	0.12*	0.14*	0.13*	0.13*	-	-	-	-	-	-	-	-	-
Net Income	-116.5%	-3.28	20.00	19.00	4.00	24.00	53.00	50.00	45.00	33.00	45.00	43.00	35.00	45.00	93.00	32.00	-0.37	9.00	15.00	-27.61	30.00	33.00
Net Income Margin	-40.1%	0.03*	0.04*	0.07*	0.08*	0.11*	0.12*	0.11*	0.11*	0.10*	0.11*	0.14*	0.14*	-	-	-	-	-	-	-	-	-
Free Cashflow	-99.1%	0.00	34.00	14.00	13.00	12.00	71.00	59.00	57.00	35.00	42.00	75.00	85.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	7.8%	4,078	3,782	3,739	3,778	3,742	3,890	3,807	3,753	3,672	3,782	3,774	3,713	3,742	3,615	3,454	3,392	3,448	3,303	3,347	3,290	3,206
Current Assets	33.8%	1,416	1,058	1,027	1,051	1,029	1,161	1,196	1,137	1,066	1,154	1,104	1,032	1,039	1,237	1,152	966	1,009	858	884	869	823
Cash Equivalents	114.1%	592	276	274	309	307	457	512	447	407	513	470	397	409	470	396	361	358	199	208	176	157
Inventory	3.5%	403	390	366	354	351	325	311	320	328	317	327	324	328	310	308	359	338	316	303	297	287
Net PPE	1.5%	345	340	319	318	315	311	301	302	309	312	294	296	296	288	294	334	336	337	319	316	306
Goodwill	-1.4%	1,040	1,055	1,036	1,043	1,042	1,039	978	990	1,009	1,013	1,012	94.00	1,010	932	920	956	952	954	945	927	923
Liabilities	13.0%	2,480	2,194	2,160	2,094	2,067	2,085	2,083	2,092	2,057	2,098	2,143	2,138	2,212	2,100	2,056	2,043	2,106	1,887	1,962	1,869	1,809
Current Liabilities	-1.5%	302	307	356	377	282	321	304	296	316	340	333	319	412	401	255	212	246	331	303	315	288
Long Term Debt	0.1%	571	570	570	569	568	567	567	566	565	564	564	563	562	-2.50	470	465	460	-	-	-	-
LT Debt, Non Current	-100.0%	-	570	570	569	568	567	567	566	565	564	564	563	562	-2.50	470	465	460	-	-	-	-
Shareholder's Equity	0.6%	1,598	1,588	1,579	1,683	1,675	1,804	1,724	1,661	1,615	1,685	1,632	1,575	1,529	1,515	1,398	1,349	1,342	1,417	1,385	1,421	1,397
Retained Earnings	-0.3%	944	947	927	908	903	879	826	776	731	699	653	610	575	532	440	407	408	399	383	411	381
Additional Paid-In Capital	0.6%	1,311	1,302	1,262	1,284	1,245	1,277	1,268	1,260	1,267	1,265	1,259	1,249	1,232	1,291	1,285	1,279	1,240	1,214	1,209	1,198	1,192
Shares Outstanding	-2.9%	78.00	80.00	80.00	81.00	82.00	83.00	83.00	83.00	84.00	85.00	85.00	85.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	3,257	-	-	-	3,916	-	-	-	4,969	-	-	-	3,370	-	-	-	3,946	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-73.2%	16.00	59.00	27.00	28.00	26.00	85.00	68.00	66.00	44.00	69.00	83.00	91.00	69.00	80.00	70.00	33.00	21.00	89.00	64.00	49.00	29.00
Share Based Compensation	-3.3%	6.00	6.00	5.00	5.00	4.00	6.00	9.00	7.00	6.00	6.00	8.00	16.00	6.00	5.00	5.00	5.00	4.00	6.00	6.00	6.00	4.00
Cashflow From Investing	5.7%	-53.96	-57.23	-7.70	-15.55	-13.70	-54.82	15.00	-4.50	-14.07	-27.48	-8.47	-7.92	-117	-35.92	-6.72	-3.95	-21.48	-20.61	-108	-17.41	-15.81
Cashflow From Financing	5305.7%	359	-6.89	-49.66	-10.69	-162	-97.70	-7.64	-13.15	-133	1.00	2.00	-97.47	-3.01	21.00	-33.05	-28.55	162	-81.99	81.00	-13.19	5.00
Buy Backs	100.0%	-	-1.22	126	-	151	-	-	-	125	-	-	-	-	-	4.00	-	92.00	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IART Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Total revenue, net	$ 368,872	$ 380,846
Costs and expenses:
Cost of goods sold	162,038	147,975
Research and development	26,965	26,724
Selling, general and administrative	165,798	166,657
Intangible asset amortization	10,107	3,108
Total costs and expenses	364,908	344,464
Operating income	3,964	36,382
Interest income	5,040	4,107
Interest expense	(13,624)	(12,100)
Other (expense) income, net	(610)	1,389
(Loss) income before income taxes	(5,230)	29,778
(Benefit) provision for income taxes	(1,949)	5,552
Net (loss) income	$ (3,281)	$ 24,226
Net (loss) income per share
Basic (in dollars per share)	$ (0.04)	$ 0.30
Diluted (in dollars per share)	$ (0.04)	$ 0.29
Weighted average common shares outstanding (See Note 13):
Basic (in shares)	77,735	81,871
Diluted (in shares)	77,735	82,323
Comprehensive income (See Note 14)	$ 1,179	$ 21,028

IART Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 591,906	$ 276,402
Short-term investments	71,194	32,694
Trade accounts receivable, net of allowances of $5,050 and $4,879	241,092	259,327
Inventories, net	403,422	389,608
Prepaid Expenses	72,667	67,362
Other Current Assets	35,369	32,643
Total current assets	1,415,650	1,058,036
Property, plant and equipment, net	345,356	340,199
Right of use asset - operating leases	151,834	156,184
Intangible assets, net	1,022,609	1,067,833
Goodwill	1,040,235	1,055,462
Deferred tax assets, net	34,175	46,080
Other assets	68,365	58,194
Total assets	4,078,224	3,781,988
Current liabilities:
Current portion of borrowings under senior credit facility	19,375	14,531
Current portion of lease liability - operating leases	16,303	15,284
Accounts payable, trade	94,397	92,326
Contract liabilities	7,841	8,540
Accrued compensation	52,582	75,455
Accrued expenses and other current liabilities	111,896	100,844
Total current liabilities	302,394	306,980
Long-term borrowings under senior credit facility	1,171,036	825,563
Long-term borrowings under securitization facility	94,600	89,200
Long-term convertible securities	570,984	570,255
Lease liability - operating leases	170,082	166,849
Deferred tax liabilities	31,431	35,317
Other liabilities	139,745	199,940
Total liabilities	2,480,272	2,194,104
Stockholders’ equity:
Preferred stock; no par value; 15,000 authorized shares; none outstanding	0	0
Common stock; $0.01 par value; 240,000 authorized shares; 91,484 and 90,920 issued at March 31, 2024 and December 31, 2023, respectively	915	909
Additional paid-in capital	1,310,527	1,302,484
Treasury stock, at cost; 12,735 shares and 12,751 shares at March 31, 2024 and December 31, 2023, respectively	(646,422)	(647,262)
Accumulated other comprehensive loss	(10,646)	(15,106)
Retained earnings	943,578	946,859
Total stockholders’ equity	1,597,952	1,587,884
Total liabilities and stockholders’ equity	$ 4,078,224	$ 3,781,988

About Integra LifeSciences Holdings Corp

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

CEO	Mr. Jan De Witte
WEBSITE	integralife.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	3722

Integra LifeSciences Holdings Corp Frequently Asked Questions

What is the ticker symbol for Integra LifeSciences Holdings Corp? What does IART stand for in stocks?

IART is the stock ticker symbol of Integra LifeSciences Holdings Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Integra LifeSciences Holdings Corp (IART)?

As of Wed May 08 2024, market cap of Integra LifeSciences Holdings Corp is 1.96 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IART stock?

You can check IART's fair value in chart for subscribers.

What is the fair value of IART stock?

You can check IART's fair value in chart for subscribers. The fair value of Integra LifeSciences Holdings Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Integra LifeSciences Holdings Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IART so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Integra LifeSciences Holdings Corp a good stock to buy?

The fair value guage provides a quick view whether IART is over valued or under valued. Whether Integra LifeSciences Holdings Corp is cheap or expensive depends on the assumptions which impact Integra LifeSciences Holdings Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IART.

What is Integra LifeSciences Holdings Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, IART's PE ratio (Price to Earnings) is 48.75 and Price to Sales (PS) ratio is 1.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IART PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Integra LifeSciences Holdings Corp's stock?

In the past 10 years, Integra LifeSciences Holdings Corp has provided 0.021 (multiply by 100 for percentage) rate of return.